Literature DB >> 30922584

Association of Hemophagocytic Lymphohistiocytosis and Programmed Death 1 Checkpoint Inhibitors.

Behnam Laderian1, Kelly Koehn1, Carol Holman2, Laurel Lyckholm3, Muhammad Furqan4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30922584     DOI： 10.1016/j.jtho.2018.11.035

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  5 in total

1.  Pembrolizumab-induced Hemophagocytic Lymphohistiocytosis: an immunotherapeutic challenge.

Authors:  James Kalmuk; Jon Puchalla; Gong Feng; Anshu Giri; John Kaczmar
Journal:  Cancers Head Neck       Date:  2020-02-03

Review 2.  Clinical Management of Relapsed/Refractory Hemophagocytic Lymphohistiocytosis in Adult Patients: A Review of Current Strategies and Emerging Therapies.

Authors:  Halil Yildiz; Sarah Bailly; Eric Van Den Neste; Jean Cyr Yombi
Journal:  Ther Clin Risk Manag       Date:  2021-04-14       Impact factor: 2.423

3.  Hemophagocytic lymphohistiocytosis in two patients following treatment with pembrolizumab: two case reports and a literature review.

Authors:  Yanqiu Wei; Wei He; Wei Sun; Chaojie Wu; Denghua Ren; Xinmin Wang; Mingshun Zhang; Mao Huang; Ningfei Ji
Journal:  Transl Cancer Res       Date:  2022-08       Impact factor: 0.496

4.  Immune Checkpoint Inhibitor-Induced Hemophagocytic Lymphohistiocytosis in a Patient With Squamous Cell Carcinoma.

Authors:  Rosalyn Marar; Sruti Prathivadhi-Bhayankaram; Mridula Krishnan
Journal:  J Hematol       Date:  2022-08-30

Review 5.  Treatment-related hemophagocytic lymphohistiocytosis due to atezolizumab: a case report and review of the literature.

Authors:  Jaime Rubio-Perez; Ángel Ricardo Rodríguez-Perez; María Díaz-Blázquez; Victor Moreno-García; Manuel Dómine-Gómez
Journal:  J Med Case Rep       Date:  2022-10-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.